Bolt Biotherapeutics (BOLT) — Strategic Asset Allocation Index
Bolt Biotherapeutics (BOLT) has a Strategic Asset Allocation Index of 16.4% as of December 2025. Strategic assets (PP&E of $- plus long-term investments of $4.34 Million) total $4.34 Million, measured against net assets of $26.50 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Bolt Biotherapeutics Strategic Asset Allocation Index (2021–2025)
This chart shows how Bolt Biotherapeutics's Strategic Asset Allocation Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 16.4%, representing strategic assets of $4.34 Million against net assets of $26.50 Million USD. Explore BOLT operating cash flow to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Bolt Biotherapeutics (2021–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Bolt Biotherapeutics from 2021 to 2025, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Bolt Biotherapeutics stock valuation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 16.4% | $4.34 Million | $- | $4.34 Million | $26.50 Million | ▼ -23.6 pp |
| 2024 | 40.0% | $22.88 Million | $- | $22.88 Million | $57.20 Million | ▲ +16.6 pp |
| 2023 | 23.4% | $26.41 Million | $- | $26.41 Million | $112.74 Million | ▼ -7.2 pp |
| 2022 | 30.6% | $52.47 Million | $28.52 Million | $23.94 Million | $171.51 Million | ▼ -15.8 pp |
| 2021 | 46.4% | $115.95 Million | $30.60 Million | $85.35 Million | $250.12 Million | — |